(NASDAQ: CTNM) Contineum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 18.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.75%.
Contineum Therapeutics's earnings in 2025 is -$42,258,000.On average, 2 Wall Street analysts forecast CTNM's earnings for 2025 to be -$60,539,425, with the lowest CTNM earnings forecast at -$70,888,044, and the highest CTNM earnings forecast at -$50,190,805. On average, 2 Wall Street analysts forecast CTNM's earnings for 2026 to be -$67,783,458, with the lowest CTNM earnings forecast at -$71,922,906, and the highest CTNM earnings forecast at -$63,644,011.
In 2027, CTNM is forecast to generate -$74,251,346 in earnings, with the lowest earnings forecast at -$74,251,346 and the highest earnings forecast at -$74,251,346.